ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ — Novavax, Inc.
NVAX) a clinical-stage biopharmaceutical company, announced
today that Mr. Frederick Driscoll, Chief Financial Officer of
Novavax, will be presenting at the BIO Investor Forum. The
presentation will take place on Wednesday, October 6, 2010 at
1:00pm PT at the Palace Hotel, San Francisco, California. Mr.
Driscoll will provide a company overview, outline its competitive
position and characterize Novavax’s outlook.
Novavax, Inc. is a clinical-stage biopharmaceutical company
creating novel vaccines to address a broad range of infectious
diseases worldwide, including H1N1, using advanced proprietary
virus-like-particle (VLP) technology. The company produces potent
VLP-based recombinant vaccines utilizing new and efficient
manufacturing approaches. Novavax is committed to using its VLP
technology to create country-specific vaccine solutions. The
company has formed a joint venture with Cadila Pharmaceuticals,
named CPL Biologicals, to develop and manufacture vaccines,
biological therapeutics and diagnostics in India. Additional
information about Novavax is available on the company’s website: